Top segments and regional performance

Last year, the company generated ‪88.00 M‬ PLN, the most of which — ‪62.25 M‬ PLN — came from its top-performing segment, Novel Small Molecule Therapies, compared to ‪77.97 M‬ PLN the previous year. The greatest contribution came from European Union Members, which accounted for ‪61.60 M‬ PLN last year, with ‪69.33 M‬ PLN the year before.